Those who applied for < NineTech(267320) > hit the daily limit price in just 1 day! Achieved 31% profit!
Congratulations to everyone who applied for the free trial. ^^
※ For those who missed the “COVID-19 treatment,” no worries. We are going out strong once again.
※ Finally starting. NineTech(267320) follow-up stock hits the daily limit price on Thursday. ※
MedPacto’s CEO Kim Sung-jin revealed the mechanism of relapse and resistance in chronic myeloid leukemia through a research paper. Chronic myeloid leukemia has a high relapse rate because it fails to eliminate cancer stem cells, which cause resistance to anticancer drugs, but this study brings us one step closer to a cure!!
This research involved CEO Kim’s team, who also serves as the head of the Precision Medicine Research Center at the Next-Generation Convergence Technology Institute, along with domestic and international cancer experts such as Professor Nakahiro Kazuhito from Hiroshima University!!
“It was just too difficult to trade stocks alone.” I asked acquaintances for advice here and there, but I never made a proper profit even once. So I decided to get help from an expert and first applied for the 3-day free trial! Wow! Experts really are different. I’m still receiving the service now, and looking back, I think it was a great decision. Thank you very much.
(VIP office worker Kim Min-ji, 46 years old member)
Think of this as the last chance. If you miss this opportunity, you should quit.
It will explode exactly on “September 24”! Don’t miss out and regret it, just buy at least 100,000 KRW worth!
▶▶ Only for 30 people! “Thursday daily limit price”! ▶ Receive now ◀
※ First-come, first-served for 30 people! Both early and late rounds are over. The hero of the final injury time winning goal ※
[Today’s stocks of interest]
#MedPacto #Bion #SamsungPharmaceutical #KainosMed #CMGPharmaceutical
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

